⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DTIL News
Precision BioSciences, Inc. Common Stock
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6 th International Coalition to Eliminate HBV Cure Symposium
businesswire.com
DTIL
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status
businesswire.com
DTIL